Genmab A (GMAB) Cost of Revenue (2018 - 2026)
Genmab A (GMAB) posted Cost of Revenue of $65.0 million for Q1 2026, down 58.6% on a QoQ basis from $157.0 million in Q3 2025, and up 54.76% year-over-year from $42.0 million in Q1 2025.
Genmab A (GMAB) Cost of Revenue (2018 - 2026) Analysis & Trends
Genmab A's Cost of Revenue history runs 6 years deep, the most recent figure standing at $65.0 million for Q1 2026.
- Quarterly Cost of Revenue rose 54.76% year-over-year to $65.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $363.0 million (up 65.75% YoY) and the FY2025 annual result came in at $238.0 million, up 66.43% from the prior year.
- Cost of Revenue was $65.0 million for Q1 2026 at Genmab A, down from $157.0 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $157.0 million in Q3 2025 and bottomed at $27.0 million in Q1 2024.
- A 3-year average of $77.1 million and a median of $65.0 million in 2026 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2025 — Cost of Revenue soared 80.0% — and 2026, when it jumped 54.76%.
- Genmab A's Cost of Revenue stood at $95.0 million in 2024, then jumped by 65.26% to $157.0 million in 2025, then sank by 58.6% to $65.0 million in 2026.
- Business Quant data shows GMAB's Cost of Revenue at $65.0 million in Q1 2026, $157.0 million in Q3 2025, and $99.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Genmab A | 1.87 Bn | 349.77 Mn | 831.00 Mn | 65.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.00 Mn |
| Mar 31, 2026 | 65.00 Mn |
| Sep 30, 2025 | 157.00 Mn |
| Sep 30, 2025 | 157.00 Mn |
| Jun 30, 2025 | 99.00 Mn |
| Jun 30, 2025 | 99.00 Mn |
| Mar 31, 2025 | 42.00 Mn |
| Mar 31, 2025 | 42.00 Mn |
| Sep 30, 2024 | 95.00 Mn |
| Sep 30, 2024 | 95.00 Mn |
| Jun 30, 2024 | 55.00 Mn |
| Jun 30, 2024 | 55.00 Mn |
| Mar 31, 2024 | 27.00 Mn |
| Mar 31, 2024 | 27.00 Mn |
| Sep 30, 2020 | 8,090.00 Bn |
| Sep 30, 2020 | 8,090.00 Bn |
| Dec 31, 2019 | 7.22 |
| Dec 31, 2019 | 7.22 |
| Sep 30, 2019 | 7,220.00 |
| Sep 30, 2019 | 7,220.00 |